Abstract
Women’s health activists laid the groundwork for passage of the law that created the U.S. Food and Drug Administration in 1906. The pharmaceutical and food industries fought regulatory reforms then and continue to do so now. We examine public health activism in the Progressive Era, the postwar era and the present day. The women’s health movement began in the 1960s, and criticized both the pharmaceutical industry and the medical establishment. In the 1990s, patient advocacy groups began accepting industry funds; thousands of commercially-funded groups now dominate the advocacy landscape. As pharma funding became normalized, concerns arose regarding a) the lack of transparency and public accountability regarding funding, b) the distortion of groups’ agendas, and c) the ability of pharma-funded groups to dominate the discourse and override less well-resourced patient and health advocacy groups. Although industry-funded groups argue that funding allows them to provide useful services, the trade-off in health risks, exorbitant prices and distorted information is far too high. Sincerity is beside the point; patients and the industry have differing interests when it comes to drug safety and efficacy, drug information and drug prices. A growing resistance movement is asserting the values of its activist predecessors and opposing the prevailing culture of pharma-funded advocacy.
Similar content being viewed by others
References
Ball, D.E., K. Tisocki, and A. Herxheimer. 2006. Advertising and disclosure of funding on patient organisation websites: A cross-sectional survey. BMC Public Health 6(201).
Batt, S. 2017. Health Advocacy, Inc: How pharmaceutical funding changed the breast cancer movement. Vancouver: UBC Press.
Batt, S., and A. Fugh-Berman. 2016. Epipen furor: Patient groups take money, stay mum. The Hastings Center Bioethics Forum, August 29. https://www.thehastingscenter.org/epipen-furor-patient-groups-take-money-stay-mum/. Accessed January 7, 2020.
Best Practices. 2004. Patient advocacy & professional organizations: Building effective relationships. Chapel Hill, NC: Best Practices, LLC.
Biosimilar focus group. 2017. Biosimilar focus group project report. https://arthritis.ca/AS/media/pdf/About%20Arthritis/TAS_FocusGroupReport_Final_ENG_V5.pdf. Accessed December 3, 2019.
Boston Women's Health Book Collective, and J. Norsigian. 1970. Women and their bodies: A course. Boston, MA: Boston Women’s Health Collective and New England Free Press.
Borkowski, L., N. Dubowitz, A. Fugh-Berman, J. Podrasky, and S.F. Wood. 2015. Impacts of pharmaceutical marketing on healthcare services in the District of Columbia: Focus on gifts to organizations and influential physicians. May http://doh.dc.gov/service/prescription-drug-marketing-costs-access-rx.
Breitstein, J. 2002. Partnerships and perspectives. Pharmaceutical Executive 22(1): 68.
Cox, T.P. 2002. Forging alliances: Advocacy partners, Pharmaceutical Executive. suppl. PR Power: 8–13.
Brenner, B. 2000. Sister support: Women create a breast cancer movement. In Breast cancer: Society shapes an epidemic, edited by A.S. Kasper and S.J. Ferguson, 325–352. New York: St. Martin’s Press.
Campbell, M.A./ M.C. Howell. 1973. Why would a girl go into medicine? Medical education in the United States: A guide for women. Old Westbury, NY: Feminist Press.
Chesler, P. 1972. Women and madness. University of Michigan, MI: Allen Lane.
Delaney, M. 2005. AIDS activism and the pharmaceutical industry. In Ethics and the pharmaceutical industry, edited by M.A. Sontoro and T.M. Gorrie, 300–326. Cambridge, UK: Cambridge University Press.
Epstein, S. 1996. Impure science: AIDS, activism, and the politics of knowledge. Berkeley, CA: University of California Press.
Fugh-Berman, A., and S. Batt. 2016. EpiPens and the sale of fear. The Hastings Center Bioethics Forum, October 7. https://www.thehastingscenter.org/epipens-sale-fear/. Accessed January 7, 2020.
Gay Men’s Health Crisis. 2016. It's been 35 years since gay men's health crisis began in Larry Kramer's living room. http://www.gmhc.org/news-and-events/in-the-media/its-been-35-years-since-gay-mens-health-crisis-began-in-larry-kramers-living-room.
Geary, M.A.S. 1995. An analysis of the women's health movement and its impact on the delivery of health care within the United States. The Nurse Practitioner 20(11). https://doi.org/10.1097/00006205-199511000-00002.
Goodwin, L.S. 1999. The pure food, drink and drug crusaders, 1879–1914. Jefferson, N.C.: McFarland.
Grant, K. 2018. How pharma companies try to use funding to sway patient advocate groups. The Globe and Mail, October 22. https://www.theglobeandmail.com/canada/article-how-pharma-companies-try-to-use-funding-to-sway-patient-advocate/.
Haire, D. 1972. The cultural warping of childbirth: A special report. Seattle: International Childbirth Education Association.
Harris, G. 2009. Drug makers are advocacy group’s biggest donors. New York Times, October 21. https://www.nytimes.com/2009/10/22/health/22nami.html?_r=0. Accessed March 16, 2019.
Hilts, P.J. 2003. Protecting America's health: The FDA, business and one hundred years of regulation. NY: Knopf.
Hoffman, B. 2003. Health care reform and social movements in the United States. American Journal of Public Health 93(1): 75–85.
Jacobson, M.F. 2005. Lifting the veil of secrecy from industry funding of nonprofit health organizations. International Journal of Occupational and Environmental Health 11(4): 349–355.
Kopp, E., S. Lupkin, and E. Lucas. 2018. Patient advocacy groups take in millions from drugmakers. Is there a payback? The Washington Post, April 06. https://www.washingtonpost.com/national/health-science/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback/2018/04/06/0a75f988-397b-11e8-af3c-2123715f78df_story.html?utm_term=.2a63a0b911c8. Accessed December 3, 2019.
Li, D.G., S. Singer, and A. Mostaghimi. 2019. Prevalence and disclosure of potential conflicts of interest in dermatology patient advocacy organizations. JAMA Dermatology 155(4):460–464.
Marshall, J., and P. Aldhous. 2006. Swallowing the best advice? New Scientist 192(2575): 18–22.
McCoy, M.S., M. Carniol, K. Chockley, J.W. Urwin, E.J. Emanuel, and H. Schmidt. 2017. Conflicts of interest for patient-advocacy organizations. New England Journal of Medicine 376(9): 880–885.
McCoy, M.S. 2018. Industry support of patient advocacy organizations: The case for an extension of the Sunshine Act provisions of the Affordable Care Act. American Journal of Public Health 108(8): 1026–1030
Mills, F. 2000. Patient groups and the global pharmaceutical industry: The growing importance of working directly with the consumer. London: Urch Publishing.
Mundy, A. 2001. Hot flash, cold cash: How a once-respected women’s group went through the change—with the help of drug industry money. Washington Monthly. https://washingtonmonthly.com/2001/01/01/hot-flash-cold-cash/
Nichols, F.H. 2000. History of the women’s health movement in the 20th Century. Journal of Obstetric, Gynecologic & Neonatal Nursing 29(1): 56–64.
Pearson, C., and E. Michaud. 2002. The truth about hormone replacement therapy: How to break free from the medical myths of menopause. Roseville, CA: Prima Pub.
PhRMA. 2014. PhRMA principles on interactions with patient organizations. https://www.phrma.org/codes-and-guidelines/phrma-principles-on-interactions-with-patient-organizations
Public Citizen. 2016. Patient Groups and Big Pharma. https://www.citizen.org/sites/default/files/patients-groups-and-big-pharma-money-report.pdf
Rose, S.L. 2013. Patient advocacy organizations: Institutional conflicts of interest, trust, and trustworthiness. The Journal of Law, Medicine & Ethics 41(3): 680–687.
Rose, S.L., J. Highland, M.T. Karafa, and S. Joffe. 2017. Patient advocacy organizations, industry funding, and conflicts of interest. JAMA Internal Medicine 177(3): 344.
Rothman, S.M., V.H. Raveis, A. Friedman, and D.J. Rothman. 2011. Health advocacy organizations and the pharmaceutical industry: An analysis of disclosure practices. American Journal of Public Health 101(4): 602–609.
Ruzek, S.B., and J. Becker. 1999. The women's health movement in the United States: From grass-roots activism to professional agendas. Journal of The American Medical Women's Association 54(1): 4–8.
Seaman, B. 1969. The doctors’ case against the pill. Reprint, Alameda, CA: Hunter House, 1995.
Silverstein, K. 1999. Prozac.org. Mother Jones, November/December Issue.
World Health Organization. 2015. WHO Model List of Essential Medicines, 19th ed. https://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest Statement
Adriane Fugh-Berman directs PharmedOut, a Georgetown University research and education project that investigates the influence of pharmaceutical industry and medical device marketing on the practice of medicine. She is a paid expert witness in litigation regarding pharmaceutical and medical device marketing practices. No other authors have conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Batt, S., Butler, J., Shannon, O. et al. Pharmaceutical Ethics and Grassroots Activism in the United States: A Social History Perspective. Bioethical Inquiry 17, 49–60 (2020). https://doi.org/10.1007/s11673-019-09956-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11673-019-09956-8